HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Free via Open Access: OA OA Free Full Text Full Text (PDF) Supplementary Figure Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Midgley, C. M. Articles by Smith, G. L. Search for Related Content PubMed PubMed Citation Articles by Midgley, C. M. Articles by Smith, G. L. Agricola Articles by Midgley, C. M. Articles by Smith, G. L.

Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax

¹ Department of Virology, Faculty of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK
² Division of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK

Correspondence
Geoffrey L. Smith
geoff.smith{at}imperial.ac.uk

The antibody responses elicited by immunization of humans with vaccinia virus (VACV) strains Lister, Dryvax and NYVAC have been determined and compared. Neutralizing antibodies against intracellular mature virus (IMV) and extracellular enveloped virus (EEV), and binding antibody titres (ELISA) against the EEV protein B5, the IMV proteins A27 and H3, and VACV-infected cell lysate were measured. Lister and Dryvax induced broadly similar antibody titres, consistent with the fact that these vaccines each protected against smallpox. In contrast, antibody titres induced by NYVAC were significantly lower than those induced by both Lister and Dryvax. Moreover, there were qualitative differences with NYVAC-immunized subjects failing to induce A27-specific antibodies. These observations suggest that although NYVAC is a safer VACV strain, it does not induce an optimal VACV-specific antibody response. However, NYVAC strains engineered to express antigens from other pathogens remain promising candidate vaccines for immunization against other diseases.

A supplementary figure is available with the online version of this paper.

This article has been cited by other articles:

				R. Kennedy, V. S. Pankratz, E. Swanson, D. Watson, H. Golding, and G. A. Poland Statistical Approach To Estimate Vaccinia-Specific Neutralizing Antibody Titers Using a High-Throughput Assay Clin. Vaccine Immunol., August 1, 2009; 16(8): 1105 - 1112. [Abstract] [Full Text] [PDF]